21.03.2013 - EPFL scientists have developed a tiny, portable personal blood testing implant that sends diagnostic data through mobile phone network.
A tiny subcutaneously implanted blood testing chip can analyse several diagnostic blood parameters and then transmit the results directly to a doctor's computer. The device, developed by researchers at Swiss EPFL in Lausanne is good news for patients with chronic illness such as diabetes or those undergoing chemotherapy, whose blood needs to be monitored permanently. The implant offers an alternative to non-invasive sensors under development, which measure through the skin.
Each of the 5 sensor's surfaces can be covered with an enzyme that allows to detect a blood metabolite or with an antibody that captures specific protein markers. The few cubic centimetre-large chip's sensors can trace blood glucose, proteins, ATP or organic acids such as lactate simultaneously, Giovanni de Micheli and Sandro Carrara announced at DATE 13, Europe's largest electronics conference.
Potentially, we could detect just about anything," explains De Micheli. "But the enzymes have a limited lifespan." The enzymes currently being tested are good for about a month and a half; that's already long enough for many applications.." After the measurement, the implant emits radio waves over a safe frequency. The patch collects the data and transmits them via Bluetooth to a mobile phone, which then sends them to the doctor over the cellular network. The implant could be particularly useful in chemotherapy applications.
Currently, oncologists use occasional blood tests to evaluate their patients' tolerance to a particular treatment dosage. Additionally, in patients with chronic disorders, the implants could send alerts even before symptoms emerge, and anticipate the need for medication. The researchers hope the system will be commercially available within 4 years.
03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.
02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.
12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.
METTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications. more